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Table 2.  Pharmacokinetic parameters used for proposing PK/PD 
based limits of sensitivity and conditions favouring the prevention of 
emergence of resistance for most common organisms and systemic 
infections, together with the breakpoints set by European and American 
ad-hoc organisations  
Drug 
Typical 
daily 
dosagea 
Typical PK values 
Proposed PK/PD upper 
limit 
Breakpoints (mg/L)d 
Cmax in 
mg/L  
total/free  
(dose) 
AUC24 h 
(mg × h/L)  
total/free 
Efficacyb 
Prevention 
of 
resistancec 
EUCAST  
(S/R) 
NCCLS  
(S/I/R)  
Norfloxacin 800 mg 1.4/1.1  
(400 mg 
PO) 
14/11 0.1–0.4 0.1 ≤0.5/>1e ≤4/8/>16j 
Drug 
Typical 
daily 
dosagea 
Typical PK values 
Proposed PK/PD upper 
limit 
Breakpoints (mg/L)d 
Cmax in 
mg/L  
total/free  
(dose) 
AUC24 h 
(mg × h/L)  
total/free 
Efficacyb 
Prevention 
of 
resistancec 
EUCAST  
(S/R) 
NCCLS  
(S/I/R)  
Ciprofloxacin 1000 mg 2.5/1.75  
(500 mg 
PO) 
24/18 0.2–0.8 0.2 ≤0.5/>1f 
(≤0.125/>2)g 
≤1/2/>4k 
Ofloxacin 400 mg 4/3  
(400 mg 
PO) 
40/30 0.3–0.9 0.4 ≤0.5/>1f 
(≤0.125/>4)g 
≤2/4/8l 
Levofloxacin 500 mg 4/2.8  
(500 mg 
PO) 
40/28 0.3–0.9 0.3 ≤1/>2f 
(≤2/>2)h 
≤2/4/8l 
Moxifloxacin 400 mg 3.1/1.8  
(400 mg 
PO) 
35/21 0.2–0.7 0.2 ≤0.5/>1)e 
(≤0.5/>0.5)i 
≤1/2/4m 
EUCAST, European Committee on Antimicrobial Susceptibility Testing (http://www.eucast.org) [241]. 
NCCLS, National Committee for Clinical Laboratory Standards (Clinical and Laboratory Standards 
Institute) (http://www.nccls.org). 
S, susceptible; I, intermediately resistant; R, resistant. 
a
 In patients with no gross abnormality of the excretory functions, and for most common tissue-based 
infections (thus excluding simple cystitis); based on recent typical ‘Summary of Product Characteristics’ 
(SPC, or ‘labelling’ in Europe). Recent guidelines, and SPC in some countries, suggest higher dosages 
for ciprofloxacin (up to 1200 mg/day), ofloxacin (up to 800 mg/day), and levofloxacin (750–
1000 mg/day). Because the pharmacokinetics of registered quinolones are linear with respect to doses 
(within the limits of the agents registered), adaptation of the figures of Cmax and AUC24 h for doses other 
than those shown here can be done by simple extra- or intrapolation. 
b
 Based on a free AUC24 h/MIC ratio ranging from 30 (pneumococcocal infection/immunocompetent 
host) to 100 (Gram-negative infection/immunoimpaired host); see discussion in text in support of these 
values as average means for free concentrations. 
c
 Based on a minimal Cmax/MIC ratio of 10, considered to encompass the ‘mutant prevention 
concentration’ of most susceptible isolates (see text for discussion). Application of this criterion will also 
meet the requirement for larger AUC24 h/MIC ratios than needed for efficacy. 
d 
For organisms within the main indications. 
e 
Enterobacteriaceae only (Pseudomonas is considered to be non-susceptible). 
f 
For most Gram-negative organisms, including Pseudomonas; 1 for Staph. aureus with high-dose 
therapy. 
g
 Values in parentheses refer to Streptococcus pneumoniae, where the wild-type population is not 
considered susceptible to ciprofloxacin or ofloxacin, and is therefore categorised globally as 
‘intermediate’. 
h
 For Strep. pneumoniae and levofloxacin, the breakpoint was increased to 2 to avoid dividing the wild-
type population (see [242] for a typical example from France), but this breakpoint relates to high dose 
therapy. 
i
 For Strep. pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. 
j
 Enterobacteriaceae and P. aeruginosa. 
k 
Staphylococcus aureus, Enterobacteriaceae and P. aeruginosa. 
 
l
 Strep. pneumoniae, Staph. aureus, Enterobacteriaceae and P. aeruginosa.  
m
 Strep. pneumoniae. 
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